Since before the end of the transition period on 31 December 2020, MHRA has been working hard to provide the guidance the industry needs to become familiar with the pharmacovigilance requirements for UK marketing authorization holders (MAH) which are set out in a revised legal framework. In this blog post, they’ve pulled together all the sources of guidance that they’ve published so far, as well as information on where to go if there are still questions.
Read more online